Stellantis and Leapmotor Adjust B10 EV Production Plans
Stellantis, in partnership with Leapmotor, has abandoned plans to produce its second electric vehicle (EV) model, the B10, at its Polish facility. The decision follows pressure from the Chinese government, which instructed automakers to halt large investments in EU nations that supported the imposition of tariffs on Chinese EVs.
Shift to New Production Locations
Instead of Poland, the joint venture is now considering Stellantis’ factories in Eisenach, Germany, and Trnava, Slovakia, as potential sites for manufacturing the B10 electric crossover. This shift comes after Poland, a proponent of the EU tariff on Chinese EV imports, was identified as an unfavorable location for investment by the Chinese Ministry of Commerce.
EU Tariff Controversy
Poland, along with nine other EU members, supported the 45% tariff on Chinese EVs, which took effect on October 30. Conversely, Germany and Slovakia, along with several other EU countries, opposed the move. This has led to uncertainties about the B10's production location, with the impact of these geopolitical tensions still unfolding.
Impact of Geopolitical Pressure
The change in production sites may lead to higher production costs in Germany due to higher utility and labor expenses compared to Poland. Despite the shift, Stellantis and Leapmotor remain committed to making the B10 a key model for markets outside China, including Europe.
For further reading, you can check out the following sources:
- Chinese Automakers Reassess Investment in Europe Amid Tariff Dispute
- Stellantis and Leapmotor Adjust EV Plans in Response to EU Tariffs
- EU Members Clash Over Tariffs on Chinese-Made Electric Vehicles


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Washington Post Publisher Will Lewis Steps Down After Layoffs
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 



